Key Highlights

  • Net income landed at USD 19.2 million, or USD 0.26 a diluted share, for the third quarter of 2026. Zevra Therapeutics (NASDAQ:ZVRA) disclosed the figure in a filing dated November 3, 2026, after a Deficit of USD 0.5 million a year before.
  • Revenue advanced to USD 37.8 million, up from USD 26.1 million, and operating profit grew to USD 11.6 million from a USD 4.1 million base.
  • Year-to-date Revenue hit USD 113.6 million against USD 72.3 million earlier, and a USD 43.3 million gain was recognized after selling future royalties, intellectual property and other assets.
  • Long-term borrowings fell to nothing by September 30, 2026, from USD 61.9 million at the end of 2025, and cash plus investments is roughly USD 270.9 million by our own calculation.

A Shift From Losses to USD 19.2 Million in Earnings

The company behind MIPLYFFA and OLPRUVA, Zevra Therapeutics (NASDAQ:ZVRA), filed its 10-Q on November 3, 2026, for the quarter that closed September 30, 2026. Sales of USD 37.8 million came in roughly 45% above the USD 26.1 million booked in the same quarter of 2025, a rise we calculated from the two reported amounts. Operating profit more than doubled to USD 11.6 million, while pre-tax Earnings stood at USD 19.7 million and the income tax charge was a modest USD 0.5 million. The reviewed extract contains the financial statements but no management commentary, so the reasons behind product sales go unexplained here.

Non-Cash Items Carry Part of the Bottom Line

Operations were not the only source of the gain. Within other income, a USD 5.1 million benefit came from remeasuring a Warrant and a contingent value right liability, whereas a year earlier that line had cost USD 5.5 million, and interest and other income added USD 3.0 million. Interest expense disappeared once the borrowings were paid off, having been USD 2.1 million previously. On the cost side, product cost of goods was USD 1.8 million, R&D climbed from USD 3.4 million to USD 4.9 million, and SG&A reached USD 19.1 million compared with USD 16.9 million. Because of these non-operating items, the USD 19.2 million net figure sits USD 7.6 million above operating income.

Nine-Month Results Distorted by Earlier Transactions

Through nine months, Net Income totaled USD 65.9 million, slipping from USD 71.1 million a year before even though sales expanded. The earlier period benefited from a USD 148.3 million windfall on a priority review voucher, though a USD 58.7 million intangible write-down offset part of it. This year's tally includes the USD 43.3 million gain on asset sales, a USD 2.8 million charge tied to retiring Debt and a USD 7.2 million loss on a derivative. Cash and equivalents climbed to USD 122.1 million from USD 62.4 million, and shareholders' Equity came to USD 238.9 million. Risk disclosures span commercial execution, regulatory decisions, trial timing and fundraising, which means durable profit still rests on continued sales growth.

Where Things Stand

Revenue outpacing cost growth, plus the disappearance of interest expense, is what carried Zevra Therapeutics (NASDAQ:ZVRA) into profit this quarter. About USD 7.6 million of net income came from outside operations, chiefly mostly from revaluing a non-cash Liability and from Investment income. Operating Income of USD 11.6 million is therefore the cleaner measure. The Balance Sheet looks sturdy, with no long-term debt and roughly USD 270.9 million in cash and investments by our arithmetic. Upcoming filings and any regulatory or product news should show whether sales momentum lasts.